Overview.
Prostate-specific antigen (PSA) testing can detect prostate cancer before symptoms develop, and in certain men this may prevent cancer-related death. But PSA screening also leads to false alarms, unnecessary biopsies, and treatment of cancers that may never have caused harm — a phenomenon called overdiagnosis. Understanding this trade-off is essential for making an informed, personalised decision about whether to screen.
Context: PSA screening is not a simple decision. Unlike most preventive blood tests, the evidence for population-wide benefit is modest and comes at a real cost in false positives, biopsy complications, and overtreatment. The major trials (ERSPC and PLCO) produced different headline results, which has created decades of controversy. This guide presents the evidence on both sides in plain language.
Key takeaways.
- USPSTF recommends shared decision-making for men aged 55–69 (Grade C: small net benefit for some men)
- Men aged 70 and older: USPSTF recommends against routine PSA screening
- The ERSPC trial found a 21% reduction in prostate cancer mortality at 13 years of follow-up
- To prevent one prostate cancer death, approximately 570 men needed to be screened and 18 needed treatment in the ERSPC
- Around 70–80% of elevated PSA results do not indicate prostate cancer — false positive rate is high
- An elevated PSA always requires clinical interpretation; PSA alone cannot diagnose cancer
What PSA Measures — and Its Limitations.
PSA (prostate-specific antigen) is a protein produced by prostate cells. Elevated levels can indicate prostate cancer, but also benign prostatic hyperplasia (BPH — enlarged prostate), prostatitis (inflammation), or recent ejaculation or vigorous physical activity. The key limitation is that PSA is organ-specific, not cancer-specific. A high PSA does not mean cancer, and a normal PSA does not rule it out.
- Standard reference range
- PSA < 4.0 ng/mL is traditionally used as the lower threshold for concern, though many experts now use age-adjusted ranges (< 2.5 ng/mL for men under 50; < 4.0 for men 50–70)
- What elevates PSA besides cancer
- Benign prostatic hyperplasia (BPH), prostatitis, urinary tract infection, ejaculation within 48 hours, vigorous cycling or prostate massage, prostate biopsy itself
- PSA velocity and density
- Rising PSA over time (velocity) and PSA adjusted for prostate volume (density) improve predictive value beyond a single PSA measurement
- Free vs total PSA
- A higher percentage of free PSA (free PSA / total PSA) tends to be associated with BPH rather than cancer; used to guide biopsy decisions when total PSA is borderline
The Evidence: ERSPC and PLCO Trials.
Two major randomised controlled trials — the European Randomised Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) — produced different headline findings. A subsequent analysis reconciled the discrepancy, showing both trials actually provide compatible evidence when differences in baseline screening intensity are accounted for.
- ERSPC: mortality benefit
- At 13 years of follow-up, PSA screening was associated with a 21% relative reduction in prostate cancer mortality (rate ratio 0.79, 95% CI 0.69–0.91, p=0.001) in men aged 55–69. However, 570 men needed to be screened and 18 treated to prevent one cancer death — reflecting the significant cost in overdiagnosis and overtreatment.
- PLCO: no mortality benefit in original analysis
- The PLCO trial found no reduction in prostate cancer mortality after 15 years. However, a key confound was that approximately 90% of men in the control arm had already received PSA testing outside the trial — meaning the 'unscreened' group was largely screened. This diluted any measurable difference.
- Reconciling ERSPC and PLCO
- A formal analysis by Tsodikov et al. (Annals of Internal Medicine, 2017) showed that once differences in implementation and contamination are accounted for, both trials are compatible with a 25–32% reduction in prostate cancer mortality from PSA-based screening as performed in the ERSPC. The trials are consistent, not contradictory.
USPSTF 2018 Recommendation: Grade C for Ages 55–69.
The US Preventive Services Task Force (USPSTF) updated its PSA screening guidance in 2018. Their recommendation balances the mortality reduction evidence from ERSPC against the documented harms of screening.
- Men aged 55–69
- Grade C recommendation: the decision to undergo periodic PSA-based screening should be an individual one. The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening is small for some men. Discussion of benefits and harms is required before screening.
- Men aged 70 and older
- Grade D recommendation: the USPSTF recommends against PSA-based screening. Evidence indicates that the harms — particularly overdiagnosis and overtreatment — outweigh the benefits at this age, partly because many screen-detected cancers at older ages would never have caused symptoms during the patient's lifetime.
- Men under 55
- The USPSTF does not make a specific recommendation for this age group. High-risk groups (family history, BRCA mutations, African American ancestry) may warrant earlier discussion with a clinician.
Harms of Screening: Understanding Overdiagnosis and False Positives.
The harms of PSA screening are real and affect a significant number of men who screen. These harms do not mean screening is wrong for everyone — they mean the decision requires informed weighing of individual preferences and risk.
- False positive rate
- Approximately 70–80% of men with an elevated PSA do not have prostate cancer on biopsy. Over 10 years of annual screening, roughly 15% of men will experience at least one false-positive PSA result, leading to an unnecessary biopsy.
- Biopsy complications
- Prostate biopsy carries a 1–2% risk of complications requiring hospitalisation, including infection (sepsis), bleeding, and urinary symptoms. Biopsy discomfort and psychological distress from the waiting period are also significant.
- Overdiagnosis
- An estimated 20–50% of screen-detected prostate cancers may be overdiagnosed — meaning they would never have caused symptoms or death during the patient's lifetime. Treating these cancers (surgery, radiation, hormone therapy) exposes men to harms including urinary incontinence, erectile dysfunction, and bowel problems without benefit.
- Active surveillance as a mitigation
- For low-risk screen-detected cancers, active surveillance (monitoring without immediate treatment) has significantly reduced overtreatment in recent years. Men choosing to screen should understand that a positive result does not automatically mean treatment — it triggers further evaluation and individualised decision-making.
Who Should Consider Screening — and Who Should Not.
Shared decision-making means having an informed conversation with your doctor about your personal risk factors, values, and preferences — not a blanket recommendation either way.
- Higher-risk groups where earlier/active screening discussion is more strongly indicated
- Men of African American ancestry (2–3× higher prostate cancer risk and more aggressive disease); men with first-degree relative diagnosed with prostate cancer under age 65; carriers of BRCA2 mutations (substantially elevated risk)
- Men who may lean toward screening
- Those who place high value on cancer detection even with risk of false positives and potential overtreatment; men with a strong family history; those who are comfortable with active surveillance if a low-risk cancer is found
- Men who may lean against screening
- Those who prioritise avoiding unnecessary procedures; men in excellent health for their age who accept a small risk of missing a clinically significant cancer; men over 70 unless at very high risk
- Novel biomarkers that may refine decision-making
- Tests including the Prostate Health Index (PHI), 4Kscore, and SelectMDx improve on PSA alone by more specifically identifying clinically significant cancers, reducing unnecessary biopsies. These are becoming more available alongside standard PSA testing.
FAQs.
What PSA level should prompt a biopsy?
There is no single universal threshold. Traditionally, a PSA above 4.0 ng/mL prompted biopsy discussion, but many urologists now consider age-specific thresholds, PSA velocity (rate of rise), free-to-total PSA ratio, and additional biomarkers. A single PSA value should not automatically lead to biopsy — further evaluation and clinical context are essential. A urologist will typically reassess after confirming the result, ruling out reversible causes of PSA elevation, and considering additional tests.
Is it true that PSA screening does more harm than good?
That is an oversimplification of a nuanced evidence base. For men aged 55–69 who engage in shared decision-making and understand the trade-offs, PSA screening can prevent prostate cancer deaths — but the absolute benefit is modest (the ERSPC showed 570 men needed to screen for one death prevented). The harms — false positives, unnecessary biopsies, overdiagnosis, and overtreatment — are real but can be mitigated by active surveillance for low-risk cancers and improved biomarkers. Whether the benefit outweighs the harm is a personal decision that depends on individual values and risk factors.
How often should PSA be tested if I decide to screen?
If initial PSA is low (< 1 ng/mL), screening every 2–4 years is generally appropriate. If PSA is 1–2 ng/mL, annual or biennial testing is common. If PSA is 3–4 ng/mL (borderline), annual monitoring with possible urological referral is typical. The frequency and approach should be discussed with your doctor based on your baseline PSA level, age, and risk factors.
Does an elevated PSA always mean cancer?
No. The majority of elevated PSA results — approximately 70–80% — are not caused by cancer. PSA rises with benign prostatic hyperplasia (an enlarged but non-cancerous prostate, which is very common in men over 50), prostatitis, urinary tract infection, and even recent ejaculation or vigorous exercise. An elevated PSA is the beginning of a diagnostic pathway, not a cancer diagnosis. Further testing and clinical evaluation are always required.
My PSA is 4.8 ng/mL. Should I be worried?
A PSA of 4.8 ng/mL warrants attention and discussion with your doctor, but does not confirm cancer. Your doctor will likely want to: repeat the PSA to confirm (an isolated elevation can be transient), rule out prostate infection or BPH as causes, consider your age and overall risk profile, possibly order additional biomarkers (free PSA, PHI, 4Kscore), and refer to a urologist if the result is confirmed. Do not interpret a single PSA result in isolation.